Health
Bristol Myers Squibb Presents Two Late-Breaking Presentations Demonstrating Sotyktu (deucravacitinib) Efficacy in Psoriatic Arthritis and Systemic Lupus Erythematosus
PRINCETON, N.J., October 27, 2025--BMS Presents Two Late-Breaking Presentations Demonstrating Sotyktu (deucravacitinib) Efficacy in Psoriatic Arthritis and Systemic Lupus Erythematosus
About this update from Bristol-myers Squibb Company
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1497,"height":206,"url":"https://media.zenfs.com/en/business-wire.com/5fcd427d20cc592ebd5c9acc5eafa2bd"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/pcKruof1nJJbolMF6N5wdQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTEzMjtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/5fcd427d20cc592ebd5c9acc5eafa2bd","width":960,"height":132},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/Q4mXS026N1BRytNCihnjhQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD0zMzA7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/5fcd427d20cc592ebd5c9acc5eafa2bd","width":1200,"height":165}},"lazy":false},{"type":"text","content":"New data from the pivotal Phase 3 POETYK PsA-1 trial demonstrated that Sotyktu improved and maintained meaningful clinical responses, inhibition of radiographic progression and patient-reported outcomes through Week 52 in adults with active psoriatic arthritis","length":260,"tagName":"p","attribs":{}},{"type":"text","content":"Safety in POETYK PsA-1 through Week 52 was consistent with the known Sotyktu profile, with no new signals identified","length":116,"tagName":"p","attribs":{}},{"type":"text","content":"In the Phase 2 PAISLEY-SLE and PAISLEY long-term extension studies, sustained efficacy and consistent safety were observed with up to four years of Sotyktu treatment for moderate-to-severe systemic lupus erythematosus","length":217,"tagName":"p","attribs":{}},{"type":"text","content":"PRINCETON, N.J., October 27, 2025--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE:BMY) today announced Week 52 data from the pivotal Phase 3 POETYK PsA-1 trial further confirming the efficacy and safety of Sotyktu (deucravacitinib) in adults with active psoriatic arthritis (PsA) who were not previously treated with a biologic disease-modifying antirheumatic drug (bDMARD). The company also announced new findings from an integrated analysis of the Phase 2 PAISLEY-SLE and PAISLEY long-term extension (LTE) studies supporting the safety and efficacy with up to four years of Sotyktu treatment for moderate-to-severe systemic lupus erythematosus (SLE).","length":649,"tagName":"p"},{"type":"text","content":"These data will be presented as late-breaking abstracts (POETYK PsA-1 abstract #LB20 and PAISLEY abstract #LB10) at the A...